Torrent Pharma. Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 25 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹1.9L Cr
India base business is expected to continue outperforming market growth with a focus on improving market share in key therapies and expanding the Curatio portfolio. JB Pharma margins improved to 35.3% in Q1 FY27, driven largely by cost synergies, with further incremental margin improvement expected quarterly though some reinvestment is planned.
From Torrent Pharma.'s Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Price
₹4,878
Market Cap
₹1.9L Cr
P/E Ratio
83.5
Revenue Rank
Margin Rank
How does Torrent Pharma. rank in Pharmaceuticals & Biotechnology?
Compare Torrent Pharma. against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Torrent Pharma. — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹4.2K Cr, net profit ₹364 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 3- →India base business is expected to continue outperforming market growth with a focus on improving market share in key therapies and expanding the Curatio portfolio.
- →Organic India growth excluding semaglutide showed a 15-16% trajectory; top 10 base brands are growing over 20%.
- →JB Pharma business targets double-digit growth on a consolidated basis after integration completes in 6-9 months.
- →New product launches and operating leverage in US business expected to stabilize and improve top-line and profitability.
- →Brazil market expected to return to normalized mid-teens constant currency growth following temporary channel inventory correction.
- →Germany market faces challenges but efforts on supply stabilization and tender wins ongoing with potential gradual recovery.
- →Cost synergies from JB merger driving margin expansion; revenue synergies could be clearer post-integration over next 12-18 months.
- →Rep strength expected to consolidate with some restructuring but aimed to improve field force productivity.
- →Uncertain sustainability for some growth components, with more clarity expected after 2-3 quarters of data monitoring.
📈 Profitability & Margins
Rank 3- →JB Pharma margins improved to 35.3% in Q1 FY27, driven largely by cost synergies, with further incremental margin improvement expected quarterly though some reinvestment is planned.
- →Full-year cost synergy benefits for JB Pharma likely to exceed INR100 crores, above initial targets.
- →Torrent base business EBITDA margins at 33.3% in Q1, with expected at least 0.5% annual improvement over last two years.
- →India business showing strong organic growth (~19% in Q1), with parts of the portfolio growing 15-20% plus, supporting sustained earnings growth.
- →International business showing stability/profitability in the US and recovery potential in Germany; Brazil growing strongly though with temporary channel inventory corrections.
- →Integration of JB Pharma ongoing, with possible short-term transient revenue impacts but longer-term growth and margin improvements expected.
- →No explicit EPS guidance yet; management prefers to wait for full integration by next year before updating detailed forecasts.
🏗️ Capital Expenditure Plans
Yes- →Torrent Pharma is cautiously evaluating capital allocation post-JB Pharma acquisition, which is only six months old.
- →They prefer waiting for 12-18 months to assess integration success before pursuing new opportunities.
- →The company aims not to exceed a net debt-to-EBITDA ratio of 3x to 3.5x in future investments.
- →Preference is to prioritize Indian opportunities if similar in size to international ones.
- →Currently, no major large-scale acquisition opportunities in India; may consider mid-sized international acquisitions.
- →Focus remains on optimizing current portfolio and integration before new strategic capital investments.
💰 Fundraising & Capital Structure
No information- →Torrent Pharma does not mention any immediate plans for new fundraising through debt or equity on the call.
- →Aman Mehta notes that it is still early days post-acquisition of JB Pharma, and they prefer to wait 12-18 months before considering new capital allocation.
- →Any future capital allocation decisions will be made with a net debt to EBITDA ratio target not exceeding 3x-3.5x.
- →If opportunities arise, preference is to invest in Indian market opportunities first, with international acquisitions considered in absence of major domestic opportunities.
- →There is no concrete proposal currently for distributed type arrangements or partnerships that would require fundraising.
- →Overall, the company is focused on integration and organic growth rather than immediate capital raising.
📋 Order Book & Pipeline
No informationKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Torrent Pharma. Q1 FY27 results?
India base business is expected to continue outperforming market growth with a focus on improving market share in key therapies and expanding the Curatio portfolio. JB Pharma margins improved to 35.3% in Q1 FY27, driven largely by cost synergies, with further incremental margin improvement expected quarterly though some reinvestment is planned.
What is Torrent Pharma. share price analysis?
Torrent Pharma. currently shows a below-average growth signal. The stock trades at a P/E of 83.5 with a market cap of ₹186,247 Cr. Investors should review the full earnings analysis for detailed insights.
Is Torrent Pharma. planning capital expenditure?
Torrent Pharma is cautiously evaluating capital allocation post-JB Pharma acquisition, which is only six months old.
Keep Torrent Pharma. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.